PD 098059, an inhibitor of ERK1 activation, attenuates the in vivo invasiveness of head and neck squamous cell carcinoma by Simon, C et al.
The high mortality rate of patients with advanced oral cancer most
often reflects the local and regional spread of the disease. Thus,
invasion of soft tissue can lead to the destruction of vital
structures, such as major nerves and the carotid artery, and to
overwhelming bacterial infection, the latter culminating in uncon-
trolled systemic infection. Additionally, and depending on the site
of tumour origin, invasion of important structures such as the
larynx may cause significant morbidity affecting quality of life.
Tumour cell infiltration into these surrounding structures
requires the hydrolysis of extracellular matrix components, such
as type IV collagen, laminin, fibronectin and heparan sulphates
(Tryggvason et al, 1987). This extracellular matrix hydrolysis is
largely brought about by the activity of proteases, including the
matrix metalloproteases (MMPs) (Matrisian, 1992), urokinase-
type plasminogen activator (u-PA) (Ossowski et al, 1983; Axelrod
et al, 1989; Wilhelm et al, 1995), endoglycosidases (Nakajima et
al, 1992), and cathepsins (Rempel et al, 1994).
In efforts to reduce tumour invasiveness, several attempts have
been made to block the activity of these proteases with specific
synthetic inhibitors directed at a particular enzyme (Anderson et al,
1996; Xing et al, 1997). However, the disadvantage of targeting
one protease is that the activity of other enzymes that contribute to
tumour invasiveness is unaffected. Considering this limitation, we
have argued that an agent with the potential to coordinately repress
the synthesis of multiple proteases (Gum et al, 1997; Lengyel et al,
1997) may represent a more effective way of controlling tumour
cell invasiveness. How may this be achieved? We propose a line of
attack that is aimed at AP-1-dependent transcriptional regulation
since a number of proteases, including the 92-kDa type IV collage-
nase (MMP-9) (Sato and Seiki, 1993), urokinase, stromelysin-2
and type I collagenase, which are all expressed in oral squamous
cell carcinoma (Clayman et al, 1993; Muller et al, 1993), are
controlled via AP-1 motifs in their promoters (Auble and
Brinckerhoff, 1989; Sirum and Brinckerhoff, 1989; Nerlov et al,
1991; Sato and Seiki, 1993). These motifs are bound with tran-
scription factors that are regulated, in turn, partly through the extra-
cellular signal-regulated kinase (ERK) subset of mitogen-activated
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Summary Increased mortality of patients with oral cancer largely reflects the local and regional spread of the disease. The invasiveness of
these tumours requires hydrolases which are regulated through AP-1-dependent transcriptional mechanisms. Since the amount/activity of
transcription factors bound to the AP-1 motif are regulated partly through the extracellular signal-regulated kinases (ERK1/ERK2), we
determined the effect of PD 098059, an inhibitor of ERK1/ERK2 activation, on the in vivo invasiveness of a human squamous cell carcinoma
cell line (UM-SCC-1) derived from the oral cavity. We utilized the floor of mouth musculature consisting of the mylohyoid, geniohyoid and
genioglossus muscle (which are sequentially arranged), as a natural barrier to assess tumour spread in vivo in the nude mouse. Mice were
inoculated with tumour cells superficial to the mylohyoid muscle. After 18 days, tumours were injected with either empty liposomes (control)
or liposomes containing 5 mM PD 098059 and, after an additional 22 days, the jaws of mice examined histologically. Highly infiltrative tumours,
which had penetrated the genioglossus muscle, were evident in 10/12 control mice. In contrast, in 9/12 mice in which the tumours were
injected with PD 098059, tumours did not extend beyond the mylohyoid or geniohyoid muscles. Tumours penetrated bone nutrient canals in
7/12 control mice but in only 3/12 PD 098059-treated mice. Neurotropism, characteristic of aggressive oral squamous cell carcinoma, was
evident in 6/12 control mice but was completely abolished (0/12 mice) in the PD 098059-treated mice. Using a staging system based on the
muscle layer involved, neurotropism, as well as bone involvement, we found the inhibition of invasion to be statistically significant (P < 0.01).
The reduced invasiveness of the PD 098059-liposome-treated oral cancers was associated with diminished 92-kDa type IV collagenase and
ERK1/ERK2 activities but was not a consequence of a slower tumour growth rate. This is the first study to demonstrate reduced in vivo
invasiveness of a malignancy brought about by an inhibitor of ERK1/ERK2 activation. These results raise the exciting possibility that second
generation PD 098059 congeners may reduce the spread of the disease in patients afflicted with oral cancers.
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protein kinases (MAPK) (Gille et al, 1992; Frost et al, 1994). The
ERKs are the terminal kinases in a signal transduction pathway
connecting cell surface growth factor/cytokine receptors to the
nuclear transcriptional machinery. Following growth factor/cytokine
receptor activation, Ras, c-Raf-1, and MEK-1 are sequentially acti-
vated by phosphorylation (Kyriakis et al, 1992; Huang et al, 1993;
Jelinek et al, 1994; Zheng and Guan, 1994) leading to altered tran-
scription factor activity and/or synthesis (Pulverer et al, 1991; Gille
et al, 1992; Bogoyevitch et al, 1995; Abdel-Hafiz et al, 1996;
Janknecht, 1996). Indeed, we previously demonstrated that the
elevated expression of MMP-9 and urokinase, two enzymes shown
to be involved in head and neck squamous cell carcinoma
(HNSCC) invasion (Ossowski, 1992; Clayman et al, 1993; Juarez
et al, 1993) was driven, at least in part, through a constitutively acti-
vated ERK1 (Simon et al, 1996; Gum et al, 1997; Lengyel et al,
1997). Moreover, the specific inhibition of MEK-1, an immediate
upstream activator of ERK1 by PD 098059 ([2-(2¢-amino-3¢
methoxyphenyl)-oxanaphthalen-4-one] (Alessi et al, 1995; Dudley
et al, 1995) substantially reduced both MMP-9 and urokinase
expression in cultured squamous cell carcinoma of the oral cavity
(Simon et al, 1996; Gum et al, 1997).
Accordingly, we undertook a study to determine the ability of
this specific inhibitor of ERK1 activation to attenuate the invasive-
ness of an oral cancer cell line orthotopically implanted into the
floor of mouth of nude mice. We demonstrate that PD 098059 can,
when delivered via dipalmitoyl phosphatidylcholine (DPPC) lipo-
somes as a carrier, diminish the invasiveness and abolish the
perineural invasion of tumours derived from UM-SCC-1 cells.
This attenuation in invasion was associated with reductions in
MMP-9 and ERK activities in the tumours.
MATERIALS AND METHODS
Tissue culture
UM-SCC-1 is a squamous cell carcinoma cell line originally
derived from an oral cancer (obtained from Dr Thomas Carey,
University of Michigan, Ann Arbor, MI, USA). UM-SCC-1 cells
were maintained in McCoy’s 5A culture medium supplemented
with 10% fetal bovine serum (FBS). For the collection of condi-
tioned medium for zymography, 80% confluent UM-SCC-1 cells
were incubated in serum-free medium (McCoy’s 5A medium
supplemented with 5 mg ml–1 insulin, 10 ng ml–1 epidermal growth
factor and 4 mg ml–1 transferrin) for 48 h with various amounts of
PD 098059 (kindly provided by Dr Alan Saltiel, Parke Davis, Ann
Arbor, MI, USA) entrapped in liposomes or carrier alone (lipo-
somes). The culture medium was collected and relative cell number
determined using the metabolism of the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) vital stain (Mossman,
1983).
Tumour tissue preparation
Tumour tissue extracts for gelatin-zymography and in-gel kinase
assay were prepared in buffer A (1% NP40 (octylphenoxy poly-
ethoxy ethanol), 25 mM Tris–HCl (pH 7.4), 25 mM sodium chlo-
ride, 1 mM sodium vanadate, 10 mM NaF, 10 mM sodium
pyrophosphate, 10 nM okadaic acid, 0.5 mM EGTA, and 1 mM
phenylmethylsulfonyl fluoride) after snap freezing in liquid
nitrogen and homogenization.
Preparation of liposomal PD 098059
Multilammellar vesicles containing PD 098059 were prepared as
described elsewhere (Mehta, 1996) by solubilizing dipalmitoyl phos-
phatidylcholine (DPPC) (Avanti Polar-Lipids Inc., Alabaster, AL,
USA) and drug (9:1 molar ratio) in 80% tertiary butanol. The drug-
lipid solution was then sonicated, frozen and lyophilized for 48 h.
The lyophilized powder was stored at –20°C until use. Liposomes
were prepared by reconstituting the lyophilized powder in sterile
saline solution, the suspension centrifuged at 48 000 g for 60 min,
and the pellet resuspended in normal saline. The concentration of
encapsulated drug was determined spectrophotometrically at 294 nm
after solubilization of an aliquot of the liposomes with methanol.
For qualitative determination of the uptake of liposomes into
cells, fluorescent-labelled liposomes were prepared by solubiliz-
ing DPPC and palmitoyl-(nitro-benzoxadiazol-amino-dode-
canoyl)-phosphatidylcholine (P-NBD-PC) (10:0.1 molar ratio) in
80% tertiary butanol and reconstituted in saline solution. UM-
SCC-1 cells were grown to 95% confluence and treated with
culture medium containing 200 mg ml–1 of fluorescent-labelled
liposomes for 24 h. Liposome uptake into the cells was visualized
using an inverted fluorescence microscope Nikon Diaphot (Nikon
Inc, Garden City, NY, USA) using a blue filter.
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Figure 1 Delivery of PD 098059 into the cells with neutral phospholipid liposomes. UM-SCC-1 cells were grown to 95% confluence and treated with culture
medium containing 200 mg ml–1 of fluorescent-labelled liposomes. Liposome uptake into the cells was visualized using an inverted fluorescence microscope
Nikon Diaphot using a blue filter (A). The monolayered cells were visualized by phase contrast (B)1414 C Simon et al
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Animal experiments and statistical analysis
The establishment of tumours in the floor of mouth of nude mice
was achieved essentially as described elsewhere (O’Malley et al,
1995). Briefly, athymic female nude mice (nu/nu, Harlan Sprague-
Dawley), aged 6–7 weeks, were anaesthetized by intraperitoneal
injection of ketamine/xylazine (10 and 1 mg ml–1 respectively).
Using a 250 ml syringe (Hamilton, Reno, NV, USA) and 30-gauge
needle, a 50 ml solution containing 5 ´ 106 human UM-SCC-1
squamous cells in Hank’s buffered saline was injected into the
subcutaneous tissue superficial to the mylohyoid muscle of the
nude mice. To prevent inadvertent needle placement into the
musculature, mice were placed in the supine position, the cervical
overlying skin placed on tension, the needle oriented parallel to the
floor of mouth musculature and the tumour innoculum delivered
into the subcutaneous tissue. The needle was removed with no
grossly detectable leakage. The mice were maintained in standard
animal housing for 43 days. No antibiotics or supplemental pain
control measures were employed. The animals were monitored
daily.
For the injection of liposomes with, and without, PD 098059 the
nude mice were anaesthetized as described above. After measure-
ment of gross tumour size in three dimensions, the tumour was
injected (30-gauge needle) with drug/liposome at three separate
sites (equidistant of each other) using a total volume corre-
sponding to one-quarter of the tumour volume. At this point,
tumours were 75–100 mm3. Treatment was started 18 days after
mice were inoculated with tumour cells. Tumours subsequently
received drug/liposome injections on day 23, 28 and every third
day thereafter until day 40. Mice were then sacrificed by carbon
dioxide inhalation. The treated mice showed no change in eating or
other behaviour habits over the course of the treatment. For
histopathological evaluation of invasion, animal jaws were fixed
in 10% buffered formalin, decalcified, routinely processed and
embedded in paraffin. Serial 3-mM sections were cut and stained
with haematoxylin and eosin. Histological sections were examined
by two individuals simultaneously, both blinded to the particular
treatments of each animal. The difference in invasion between PD
098059-treated and untreated groups were tested for statistical
significance using Fisher’s exact test.
Zymography on conditioned medium and tumour
tissues
Zymography was performed essentially as described previously
(Gum et al, 1996) using polyacrylamide gels containing 0.1%
(w/v) gelatin. After staining for protein with Coomassie brilliant
blue, gelatinolysis was detected as white zones in a dark field.
In-gel kinase assays for ERK activity and Western
blotting
Kinase assays were performed as described by us (Lengyel et al,
1997). Briefly, cells were extracted with buffer A (see Tumour
Tissue Preparation). Extracted protein was either immunoprecipi-
tated with 2 mg of the anti-ERK1/ERK2 antibody (Santa Cruz
Biotechnology # 93, Santa Cruz, CA, USA) and 50 mg of protein A
agarose or resolved by sodium dodecyl sulphate poliacrylamide gel
electrophoresis (SDS-PAGE) and transferred to a nitrocellulose
filter for Western blotting. For kinase assays, the pellet was washed
with buffer A and resuspended in 23 sample buffer, and the
immune complexes were electrophoresed in a polyacrylamide gel
containing myelin basic protein. The gel was treated sequentially
with buffers containing 20% 2-propanol, 5 mM 2-mercaptoethanol,
6 M guanidine hydrochloric acid and 0.04% Tween-40–5 mM
2-mercaptoethanol. The gel was then incubated at 25°C for 1 h with
10 mM adenosine 5¢-triphosphate (ATP) and 25 mCi of [(32P]ATP
in a buffer containing 2 mM dithiothreitol–0.1 mM EGTA–5 mM
0.005 0.01 0.02 5 10 20 20 40 80 5 10 20
MMP-9 —
% DMSO (control)
PD 098059 (mM)
PD 098059 (mM)
Empty liposomes
(DPPC lipid mg/ml)
Drug/DMSO Drug/liposomes
Figure 2 Reduction of MMP-9 secretion in PD 098059-treated UM-SCC-1
cells grown in vitro. UM-SCC-1 cells were treated for 48 h with the indicated
agent and/or carrier. After this time, conditioned medium was harvested and
centrifuged to remove the liposomes. Aliquots of conditioned medium
normalized for differences in cell number were analysed by zymography
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Figure 3 Establishment of tumours in the floor of mouth. UM-SCC-1 cells
were injected into the subcutaneous tissue superficial to the mylohyoid
muscle. After 18 days, mice were sacrificed and animal jaws fixed in 10%
buffered formalin. Tissue sections were stained with haematoxylin and eosin.
T, tumour; MH, mylohyoid muscle; GH, geniohyoid muscle; GG, genioglossus
muscle. Original magnification = 403Inhibition of tumour invasion and MMP-9 secretion by PD 098059 in vivo 1415
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magnesium chloride, washed in a solution containing 5%
trichloroacetic acid and 1% sodium pyrophosphate, dried, and
autoradiographed. For Western blotting the membrane was blocked
with 3% bovine serum albumin before incubation with primary
antibody and horseradish peroxidase-conjugated anti-rabbit IgG.
Immunoreactive bands were visualized by enhanced chemilumi-
nescence (ECL) (Amersham, Arlington Heights, IL, USA).
RESULTS
DPPC liposomes efficiently deliver PD 098059 into
UM-SCC-1 cells
PD 098059, a specific inhibitor of MEK-1 (Alessi et al, 1995;
Dudley et al, 1995), is a lipophilic compound and therefore
requires a carrier for in vivo delivery. Thus, in order to deliver the
drug intratumourally, we elected to use liposomes as a vehicle for
PD 098059. We first determined the ability of liposomes to deliver
PD 098059 into cultured squamous cell carcinoma cells.
Fluorescence-labelled liposomes formulated from the phospho-
lipid DPPC efficiently coalesced (Figure 1 A, B) with the surface
membranes of cultured UM-SCC-1 squamous cell carcinoma
cells, the cell line intended for use in the in vivo invasion model.
Note the absence of fluorescence from the exposed tissue culture
plate (P). To confirm that the liposome-delivered PD 098059 was
able to suppress MMP-9 synthesis, UM-SCC-1 cells were assayed
for gelatinase activity by zymography. A gelatinase activity, indis-
tinguishable in size from MMP-9 (92 kDa), was detected in the
conditioned medium from cultured UM-SCC-1 cells (Figure 2).
This activity was unaltered by increasing the amount of empty
liposomes. Conversely, the intensity of the MMP-9 activity was
decreased with increasing amount of liposome-delivered PD
098059. In fact, the decrease brought about by way of liposome-
entrapped PD 098059 was quantitatively similar to that achieved
with equivalent concentrations of PD 098059 solubilized in
dimethyl sulphoxide (DMSO).
PD 098059 attenuates in vivo invasion and abolishes
perineural invasion by tumours formed from UM-SCC-1
cells
To study the effect of PD 098059 on tumour invasion in vivo we
first developed a model that allowed us to quantitate the invasive-
ness of tumours formed from UM-SCC-1 cells. This made use of
the floor of mouth musculature in which the mylohyoid (most
superficial), geniohyoid and genioglossus (deepest) muscles are
found sequentially. Towards this end, we orthotopically implanted
5 ´ 106 UM-SCC-1 squamous cell carcinoma cells transcervically
into the subcutaneous tissue to a depth superficial to the mylo-
hyoid muscle in the floor of mouth of the nude mice. The different
muscle layers (mylohyoid – MH, geniohyoid – GH, genioglossus
– GG), which overlie each other, in the floor of mouth of the nude
mouse served as natural invasion barriers (Figure 3). A staging
system was devised based on muscle layers invaded and the
involvement of blood vessels, bone, nerves and lymph nodes
(Table 1) to allow the separation of tumours into low (stage I) and
high (stage II) invasiveness.
We then injected the drug-liposome intratumourally and
compared the extent of invasion between treatment and control
groups. To exclude a potentially inhibitory effect of the drug on
tumour establishment, mice were not treated for the first 18 days to
allow tumour formation and invasion of the adjacent mylohyoid
muscle by the tumour (T) cells (Figure 3). Then, mice were
randomized into a treatment (5 mM PD 098059-liposomes, 12 mice)
and a control group (empty liposomes, 12 mice) and treated for the
next 22 days. After this time, mice were then sacrificed and the
floor of mouth excised, stained and examined histologically. We
found that tumours which were treated with empty liposomes were
highly infiltrative (Figure 4A) with the malignant cells (T) pene-
trating (arrowhead) into the genioglossus muscle (GG). Lower
magnification (Figure 4B) clearly indicates the tumour front
(arrowhead) infiltrating the genioglossus muscle (GG) with the
lingual mucosa (LM) (superficial aspect of the tongue) clearly
evident. In order for this muscle layer to be involved, tumour cells
must traverse both the mylohyoid and the geniohyoid muscles
which underlie the genioglossus. Tumour cells (T) treated with
empty liposomes also invaded the vascular space (V) of blood
vessels (Figure 5A) and the nutrient canals of bone (B) (Figure 5B).
UM-SCC-1-formed tumours demonstrated neurotropism (Figure
5C) as evident by the presence of tumour cells (T) within the
perineural space. Neurotropism is characteristic of aggressive head
and neck squamous cell carcinomas in man and is associated with a
poor outcome for patients (Carter et al, 1983; Goepfert et al, 1984).
These findings were in sharp contrast to the results with the
treatment group. Whereas most mice (10/12, 83%) treated with
empty liposomes had highly infiltrative tumours involving the
genioglossus muscle, the majority of mice (9/12 mice (75%))
treated with PD 098059-liposomes had tumours that penetrated,
but did not extend beyond, the mylohyoid (MH) or geniohyoid
Table 1 Histological criteria defining minimally (stage I) and highly (stage II)
invasive tumours
Stage
II I
Tumour involves mylohyoid Tumour invades genioglossus
or geniohyoid muscle with, muscle with, or without, bone,
or without, vascular vascular invasion
invasion or
Invasion of any muscle with
perineural invasion or lymph
node involvement
Table 2 Treatment of tumours with PD 098059-liposomes reduces their
invasiveness
No. of mice
Stage I Stage II
Liposome only (day 40) 1 11
PD 098059-liposome (day 40) 9 3
UM-SCC-1 cells were injected into the subcutaneous tissue superficial to the
mylohyoid muscle. After 18 days, mice were treated with empty liposomes
(12 mice) or PD 098059-liposomes (12 mice). Tumours subsequently
received liposome only or drug-liposome injections on day 23, 28 and every
third day thereafter until day 40. At that point, all mice were sacrificed and
animal jaws fixed in 10% buffered formalin. Tissue sections were stained with
haematoxylin and eosin. Using the histological criteria described in Table 1,
the number of mice with minimally (stage I) or highly (stage II) invasive
tumours was enumerated.1416 C Simon et al
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(GH) muscles (Figure 6). Tumours treated with empty liposomes
also invaded bone (7/12 mice, 58%) while this was apparent in
only 3/12 (25%) mice given PD 098059-liposomes. Remarkably,
perineural invasion, a hallmark of aggressive head and neck cancer
(Carter et al, 1983; Geopfert et al, 1984), and apparent in
6/12 mice (50%) in the empty liposome treatment group was
completely abrogated (0/12) in the PD 098059-treated group
(P < 0.05) While 11 of 12 mice receiving liposomes only were
determined to have stage II (highly invasive) tumours, only three
of 12 mice treated with PD 098059-liposomes were found with
stage II tumours (Table 2). As a corollary, while one of 12 mice
receiving liposome alone had minimally invasive (stage I)
tumours, the majority (nine of 12 animals) receiving the MEK1
inhibitor were classified as having stage I tumours (Table 2).
These differences were statistically significant (Fisher-exact test,
P < 0.01).
It is unlikely that the observed effects brought about by PD
098059 reflect an inhibition of proliferative activity in the treated
tumours, since the mitotic index was not found to be significantly
different as compared to tumours in the control group (median
24 ± 13.3 and 23 ± 6.1 respectively). Further, we found a poor rela-
tionship (Student’s t-test, P = 0.31) between invasion stage and
tumour volume.
Treatment of UM-SCC-1-derived tumours in vivo with
PD 098059 reduces MMP-9 and ERK1 activity
Presumably the reduced in vivo invasiveness brought about by PD
098059 reflects, at least in part, diminished proteolysis. To address
this possibility, we analysed control and treated tumours for MMP-
9 activity. Tumours harvested from untreated mice contained a
gelatinase activity, which was indistinguishable in size (92-kDa)
from MMP-9. However, the intensity of this activity was substan-
tially reduced in tumours treated with the MEK1 inhibitor (Figure
7A). In contrast, we did not observe a reduction in the amount of a
gelatinase activity, which was indistinguishable in size (72-kDa)
from MMP-2.
To confirm that the PD 098059 in fact reduced ERK1 activity,
residual tumour tissue from histological and protease determina-
tions was homogenized. The resulting tumour extract was then
incubated with an anti-ERK1/ERK2 antibody and the immuno-
precipitated material subjected to an in-gel kinase assay. ERK1
activity was reduced in a PD 098059-treated tumour compared
with a control tumour that had received only empty liposomes
(Figure 7B). The reduced ERK1 activity was not a consequence of
a smaller amount of the MAPK protein as shown by Western
blotting (Figure 7C). Taken together, these data suggest that the
prevention of ERK activation by the MEK inhibitor PD 098059
reduces tumour cell invasion in vivo possibly as a consequence of
reducing the expression of the metalloproteinase MMP-9.
DISCUSSION
The local and regional spread of head and neck squamous cell
carcinomas is most often life-threatening to patients afflicted with
this malignancy. Thus, there is an urgent need to control the ability
of the tumour cells to spread locally and regionally. Although
tumour invasion is a complex process, degradation of the
surrounding extracellular matrix is a prerequisite step and accom-
plished largely via proteolysis (Tryggvason et al, 1987; Wilhelm et
al, 1989). Accordingly, a reduction in protease synthesis would be
expected to attenuate tumour invasiveness. However, achieving this
goal is complicated by two issues; firstly that multiple enzymes are
A
T
GG
B
T
GG
Figure 4 Tumours treated with empty liposomes invade the genioglossus
muscle. UM-SCC-1 cells were injected into the subcutaneous tissue
superficial to the mylohyoid muscle. After 18 days, mice were treated with
empty liposomes. After an additional 22 days, mice were sacrificed and
animal jaws fixed in 10% buffered formalin. Tissue sections were stained with
haematoxylin and eosin. (A) Original magnification = 1003. (B) Original
magnification = 403. T, tumour; GG, genioglossus muscle; arrowhead,
infiltrating tumour cells; LM, lingual mucosaInhibition of tumour invasion and MMP-9 secretion by PD 098059 in vivo 1417
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required for invasiveness (Ossowski, 1992), and second that the
regulation of expression of these hydrolases is brought about by the
concerted action of divergent mitogens such as transforming
growth factor-a (Jensen and Rodect, 1993; Lyons et al, 1993) and
hepatocyte growth factor (Pepper et al, 1992). Thus, the targeting
of any one hydrolase or any one mitogen may prove inefficient in
repressing tumour invasiveness. We explored instead the potential
of antagonizing a signalling cascade utilized by multiple growth
factors for ‘driving’ the expression of divergent proteases. Several
hydrolases (MMP-9, urokinase, stromelysin-2, type I collagenase)
(Sirum and Brinckerhoff, 1989; Auble and Brinckerhoff, 1991;
Nerlov et al, 1991; Sato and Seiki, 1993) implicated in the spread of
oral squamous cell carcinoma are AP-1-regulated, and since the
amount and/or activity of transcription factors bound to this motif
is regulated through ERK1 (Pulverer et al, 1991; Gille et al, 1992;
Agarwal et al, 1995; Bogoyevitch et al, 1995), we undertook a
study to determine if an inhibitor (PD 098059) of this MAPK atten-
uated the invasiveness of orthotopically-implanted tumours estab-
lished from UM-SCC-1 cells. We report for the first time a
dramatic anti-invasive effect of this agent in vivo. Equally impor-
tant, treatment of tumours with PD 098059 completely abrogated
neurotropism. This is an important observation since head and neck
cancer patients with perineural invasion have a high incidence of
local recurrence (47%) and metastasis (35%) (Geopfert et al, 1984;
Rowe et al, 1992).
Although there is ample evidence for a role of ERK1 in growth
control (Sontag et al, 1993), the diminished invasiveness produced
by PD 098059 is unlikely to be due to an anti-proliferative effect
for three reasons. First, the mitotic index in PD 098059-treated
versus control tumours was similar. Second, we found no correla-
tion between the size of the tumours and their invasiveness. Third,
we found little evidence of diminished growth of cultured
UM-SCC-1 cells (Simon et al, 1996) using concentrations of PD
098059 employed in the current study.
In our study we observed a substantial, but incomplete, attenua-
tion of in vivo invasion and MMP-9 expression brought about by
PD 098059. This might be explained in different ways. For
example, the drug may be incompletely distributed throughout the
tumour; a real possibility considering that the PD 098059 was
injected intratumourally rather than systemically administered.
However, our observation of a substantial reduction in ERK
activity in PD 098059-treated tumours would argue against this
possibility. It is more probable that protease expression is regu-
lated by both PD 098059-sensitive and -insensitive signalling
cascades. Indeed, we previously demonstrated that MMP-9
expression and in vitro invasion can be partially regulated via the
p38 MAPK (Simon et al, 1998).
Although we showed a clear reduction in MMP-9 activity in PD
098059-treated tumours, it is unlikely that the reduced invasive-
ness of the tumours is entirely a consequence of the repression of
this metalloproteinase. It is more probable that the repression of
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Figure 5 Tumours treated with empty liposomes invade the vascular space,
bone and nerves. Tumour generation, tissue processing and staining were as
described in the legend to Figure 4. V, vascular space; T, tumour; B, bone; N,
nerve. (A) Original magnification = 2003. (B) Original magnification = 1003.
(C) Original magnification = 2003
MH
T
SG
GH
Figure 6 Reduced invasiveness of tumours treated with PD 098059-
liposomes. Tumour generation, tissue processing and staining were as
described in the legend to Figure 4. MH, mylohyoid muscle; GH, geniohyoid
muscle; SG, salivary gland; T, tumour. Original magnification = 4031418 C Simon et al
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multiple AP-1-dependent proteases such as urokinase, type I colla-
genase, and stromelysin 2 (Sirum and Brinckerhoff, 1989; Auble
and Brinckerhoff, 1991; Nerlov et al, 1991; Sato and Seiki, 1993),
all of which have been implicated in the progression of head and
neck cancer (Clayman et al, 1993; Muller et al, 1993), is respon-
sible for the overall reduction in tumour invasiveness. Indeed, in a
previous study, we showed that the synthesis of the u-PA in UM-
SCC-1 cells was reduced by PD 098059 (Simon et al, 1996). On
the other hand, we did not detect a decrease in the 72-kDa type IV
collagenase (MMP-2) and this is consistent with the absence of
AP-1-binding motifs in the promoter sequence (Huhtala et al,
1990).
The ability to reduce tumour cell infiltration into surrounding
and adjacent tissues may ultimately be of therapeutic value for
patients afflicted with oral squamous cell carcinoma where local
and regional invasion represents a major challenge to the clinician.
Our findings raise the exciting possibility that second-generation
analogues of PD 098059 may, in an adjuvant setting, diminish the
spread of residual disease following surgery/irradiation.
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